Table 2.
Autoantibody prevalence according to the clinical manifestations.
| Autoantibodies (assay) n (%) | Arterial or venous thrombosis (n = 9) | Pregnancy morbidity (n = 61) | Spontaneous abortions (n = 41) | Intrauterine death of a normal fetus (n = 27) | Premature births (n = 4) |
|---|---|---|---|---|---|
| Anti-anti-CL [by thin-layer chromatography (TLC)-immunostaining] | 7 (77.8) | 38 (62.2) | 25 (41.0) | 18 (29.5) | 3 (4.9) |
| Anti-CL/Vim | 4 (44.4) | 27 (44.3) | 15 (24.6) | 13 (21.3) | 1 (1.6) |
| Anti-PS/PT | 1 (11.1) | 6 (9.8) | 3 (4.9) | 3 (4.9) | 0 |
| Anti-CL IgA | 0 | 2 (3.3) | 2 (3.3) | 0 | 0 |
| Anti-β2GPI IgA | 0 | 1 (1.6) | 1 (1.6) | 0 | 0 |
| Anti-CL (by TLC-immunostaining) + anti-CL/Vim | 3 (33.3) | 16 (26.2) | 11 (18.0) | 8 (13.1) | 1 (1.6) |
| Anti-CL (by TLC-immunostaining) + anti-CL/Vim + anti-PS/PT | 0 | 2 (3.3) | 2 (3.3) | 0 | 0 |
| No autoantibodies | 1 (11.1) | 11 (18.0) | 10 (16.4) | 3 (4.9) | 1 (1.6) |
CL, cardiolipin; CL/Vim, cardiolipin/vimentin; PS/PT, phosphatidylserine/prothrombin; β2GPI, beta2Glycoprotein I.